Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $54.99
    -3.20 (-5.50%)

    Market Cap: $7.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    10X Genomics Inc (TXG) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    10X Genomics (TXG) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, 10X Genomics reported EPS of -$0.15, above the -$0.29 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(21/30)
    Avg Surprise
    +20.14%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.22
    Range-$0.33 - -$0.07
    16 analysts
    Revenue Consensus
    $179.68M
    Range$163.56M - $190.99M
    17 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.03
    Range-$0.03 - -$0.03
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.01-400.0%
    60d ago$0.02-250.0%
    30d ago$0.02-250.0%
    7d ago-$0.030.0%
    Current-$0.03
    Revenue Consensus
    $167.33M
    Range$156.88M - $180.00M
    10 analysts

    Next Report

    TXG has an expected report date of Feb 10, 2027.

    TXG Earnings Call

    The latest TXG earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, TXG beat 21 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $150.67M, up 1.1% from $149.00M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.15-$0.29N/A+48.28%BeatN/A22 up, 0 downNov 5, 2026$150.67M
    Jun 30, 2026-$0.14-$0.23N/A+39.13%Beat-150.0%32 up, 0 downAug 6, 2026$151.04M
    Mar 31, 2026$0.07-$0.06-$0.09 - -$0.03+216.67%BeatN/A30 up, 0 downMay 7, 2026$150.84M
    Dec 31, 2025$0.07-$0.04-$0.17 - $0.04+275.00%BeatN/A30 up, 0 downFeb 12, 2026$166.03M
    Sep 30, 2025-$0.02-$0.07-$0.07 - -$0.07+71.43%BeatN/A20 up, 2 downNov 6, 2025$149.00M
    Jun 30, 2025$0.28-$0.35N/A+180.00%Beat+2700.0%22 up, 0 downAug 7, 2025$172.91M
    Mar 31, 2025-$0.10-$0.29-$0.33 - -$0.25+65.52%BeatN/A20 up, 1 downMay 8, 2025$154.88M
    Dec 31, 2024-$0.14-$0.11-$0.30 - -$0.01-27.27%MissN/A31 up, 0 downFeb 12, 2025$165.02M
    Sep 30, 2024-$0.02-$0.26N/A+92.31%BeatN/A173 up, 0 downOct 29, 2024$151.65M
    Jun 30, 2024$0.01-$0.23N/A+104.35%BeatN/A171 up, 0 downAug 8, 2024$153.10M
    Mar 31, 2024-$0.20-$0.39-$0.65 - -$0.30+48.72%BeatN/A151 up, 0 downApr 30, 2024$141.01M
    Dec 31, 2023-$0.41-$0.36-$0.49 - -$0.22-13.89%Miss-295.2%154 up, 1 downFeb 15, 2024$183.98M
    Sep 30, 2023-$0.10-$0.04N/A-150.00%MissN/A130 up, 1 downNov 2, 2023$153.64M
    Jun 30, 2023-$0.14-$0.05N/A-180.00%MissN/A130 up, 0 downAug 3, 2023$146.82M
    Mar 31, 2023-$0.07-$0.16N/A+56.25%BeatN/A121 up, 1 downMay 3, 2023$134.28M
    Dec 31, 2022$0.21-$0.20N/A+205.00%BeatN/A111 up, 0 downFeb 15, 2023$156.23M
    Sep 30, 2022-$0.07-$0.24N/A+70.83%BeatN/A80 up, 0 downNov 2, 2022$131.07M
    Jun 30, 2022-$0.25-$0.30-$0.48 - -$0.23+16.67%BeatN/A91 up, 0 downAug 8, 2022$114.61M
    Mar 31, 2022-$0.14-$0.33-$0.43 - -$0.18+57.58%BeatN/A70 up, 0 downMay 4, 2022$114.50M
    Dec 31, 2021-$0.16-$0.03-$0.16 - $0.01-433.33%MissN/A81 up, 0 downFeb 16, 2022$143.53M
    Sep 30, 2021-$0.15-$0.21-$0.26 - -$0.04+28.57%BeatN/A90 up, 0 downNov 3, 2021$125.30M
    Jun 30, 2021-$0.11-$0.23-$0.60 - -$0.05+52.17%BeatN/A9N/AAug 4, 2021$115.84M
    Mar 31, 2021-$0.11-$0.19-$0.51 - -$0.10+42.11%BeatN/A9N/AMay 5, 2021$105.82M
    Dec 31, 2020-$0.08-$0.07-$0.49 - -$0.06-14.29%MissN/A8N/AFeb 17, 2021$112.22M
    Sep 30, 2020-$0.25-$0.31-$0.39 - -$0.24+19.35%BeatN/A7N/ANov 10, 2020$71.82M
    Jun 30, 2020-$0.41-$0.49-$0.64 - -$0.41+16.33%BeatN/A6N/AAug 11, 2020$42.91M
    Mar 31, 2020-$0.20-$0.13-$0.20 - -$0.08-53.85%MissN/A5N/AMay 11, 2020$71.91M
    Dec 31, 2019-$0.07-$0.13-$0.15 - -$0.07+46.15%BeatN/A4N/AFeb 18, 2020$75.29M
    Sep 30, 2019-$0.33-$0.10N/A-230.00%MissN/A2N/ANov 7, 2019$61.21M
    Jun 30, 2019-$0.16-$0.11N/A-45.45%MissN/AN/AN/ASep 11, 2019$55.82M
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.23, a profit after a loss of $0.35 per share the year before. It was -$0.56 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.23N/A
    Dec 31, 2024-$0.35N/A
    Dec 31, 2023-$0.72N/A
    Dec 31, 2022-$0.25N/A
    Dec 31, 2021-$0.53N/A
    Dec 31, 2020-$0.94N/A
    Dec 31, 2019-$0.56N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,07514
    2026Q2Jun 30, 20267,07717
    2026Q1Mar 31, 20266,48917
    2025Q4Dec 31, 20258,40018
    2025Q3Sep 30, 20256,53617
    2025Q2Jun 30, 20256,37317
    2025Q1Mar 31, 20258,43118
    2024Q4Dec 31, 20247,69819

    2026Q3 Earnings Call

    Opening remarks

    Cassie Corneau Senior Director and Head of Investor Relations and Strategic Finance Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxonov, our CEO and Co-Founder, and Adam Taich, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue. With that, I will now turn the call over to Serge.

    Serge Saxonov CEO and Co-Founder Thanks, Cassie, and good afternoon, everyone. Revenue for the third quarter was $151 million, up 1% year over year. The biggest highlight was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we're incredibly excited to be putting instruments in customers' hands. The rest of the business also performed well, driven by continued strength in consumables. Adam will cover the financial results and outlook in more detail. Now, stepping back, it's worth reflecting on this remarkable point in time as progress in AI is reshaping so much of the world. Many believe that AI's greatest promise is in accelerating science and advancing human health. We agree, and the key bottleneck is the data. Biology is incredibly complex. Capturing that complexity requires measuring biological systems at massive scale and high resolution. It requires measurements of molecules, cells, and tissues across vast numbers of samples, conditions, and contexts. This is precisely why we started 10x and why we have built our single-cell and spatial technologies.

    Frequently Asked Questions About TXG

    When is 10X Genomics's next earnings date?

    10X Genomics's next earnings report is expected for Feb 10, 2027.

    Did TXG beat earnings estimates last quarter?

    Yes. 10X Genomics reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.29 estimate, a 48.28% surprise.

    What EPS do analysts expect from TXG next quarter?

    The consensus EPS estimate for 10X Genomics for the quarter ending Dec 31, 2026 is -$0.22 from 16 analysts, with estimates from -$0.33 to -$0.07.

    How often does TXG beat earnings estimates?

    10X Genomics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +108.59%.